What is Holoclara?
Holoclara stands at the forefront of biotechnology innovation, uniquely positioned as the first company to engineer safe, orally administered therapies derived from gut roundworms. Leveraging decades of preclinical data, Holoclara mines potent immunomodulatory molecules from these worms, aiming to provide relief for millions suffering from allergic and autoimmune conditions. Founded and directed by physician-scientist Andrea Choe, the company's scientific foundation is built upon a deep understanding of worm biology and its therapeutic applications. Holoclara's approach targets historically untreatable diseases, signaling a significant advancement in medical science.
How much funding has Holoclara raised?
Holoclara has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2024): $16M with participation from FreeFlow Ventures, Horizons Ventures, and BOLD Capital Partners
Key Investors in Holoclara
FreeFlow Ventures
FreeFlow Ventures is a venture builder and studio based in India, focusing on early-stage to growth-stage startups. They provide investment facilitation, technology development, and HR solutions, aiming to grow and succeed with their portfolio companies.
Horizons Ventures
Horizons Ventures invests in deep science and technology aimed at advancing humanity. They support innovative projects with the potential for transformative changes, focusing on sectors that can lead to a significantly improved future.
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm that invests in entrepreneurs and technologies aiming to transform the world. They focus on emerging science and technologies that can disrupt large markets and address significant global challenges.
What's next for Holoclara?
The recent major strategic investment signifies a critical growth phase for Holoclara, likely enabling the company to accelerate its research and development efforts, expand its clinical trial pipeline, and scale its operational capacity. This enterprise-level backing suggests strong investor confidence in Holoclara's unique therapeutic modality and its potential to disrupt the treatment landscape for chronic immune-related disorders. The company is poised to further solidify its position as a leader in harnessing the power of helminth-derived therapeutics.
See full Holoclara company page
